We evaluated responses to the treatment and long-term outcomes of chronic myeloid leukemia patients treated with imatinib as first-line treatment in routine clinical setting from two countries with centralized tyrosine kinase inhibitors (TKIs) treatment. We assessed prognostic significance of European LeukemiaNet (ELN) 2006- and 2009-defined responses and the prognostic value of molecular responses at defined time points on 5-year survivals. Among the cumulative rates of incidence of hematologic, cytogenetic, and molecular responses and all important survival parameters, we evaluated the prognostic significance of different BCR-ABL transcript-level ratios (≤1%; >1%-≤10%; >10%) at 3, 6, 12, and 18 months (n = 199). The ELN optimal response criteria and their predictive role were significantly beneficial for event-free survival at all given time points. We found significant improvement in survivals of patients with BCR-ABL lower than 10% in the 6th and 12th months. Significantly better outcome was found in patients who achieved major molecular response (MMR) in the 12th month. The cumulative incidences of complete cytogenetic response (CCyR) and MMR were significantly associated with the molecular response in the 3rd month. The ELN response criteria and their predictive role were helpful at given time points; however, the 2009 definition did not significantly alter the prognostic accuracy compared with that of the 2006 definition. The significant value was observed for cytogenetic responses at the 6th and 12th month. Moreover, progression-free and event-free survivals were improved with MMR at the 12th month.

Institute of Hematology and Blood Transfusion Prague Czech Republic

Zobrazit více v PubMed

Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet. 2007;379:342–350. PubMed

Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood. 2007;111:2828–2935. PubMed

Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 2006;355:2308–2417. PubMed

Deininger M, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, et al. MD11 International Randomized Study of Interferon and STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib. Blood. 2009;114 (ASH Annual Meeting Abstract no. 462)

Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendation from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809–1820. PubMed

Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J. Clin. Oncol. 2009;27:6041–6051. PubMed PMC

Hughes T, Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev. 2006;20:29–41. PubMed

Martinelli G, Iacobucci I, Rosti G, Pane F, Amabile M, Castagnetti F, et al. Prediction of response to imatinib by prospective quantitation of BCR-BL transcript in late chronic phase chronic myeloid leukemia patients. Ann. Oncol. 2006;17:495–502. PubMed

Paschka P, Müller MC, Merx K, Kreil S, Schoch C, Lahaye T, et al. Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia. 2003;17:1687–1694. PubMed

Hanfstein B, Müller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) Leukemia. 2012;26:2096–2102. Mar 26. doi: 10.1038/leu.2012.85. PubMed

Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J. Clin. Oncol. 2012;30:232–238. PubMed PMC

Müller MC, Erben P, Saglio G, Gottardi E, Nyvold CG, Schenk T, et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia. 2008;22:96–102. PubMed

Müller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T, et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia. 2009;23:1957–1963. PubMed

Müller MC, Munjal U, Erben P, Lion T, Mitterbauer-Hohendanner G, El Housni H, et al. Stability of conversion factors for BCR-ABL monitoring – implications for the frequency of validation rounds. Blood. 2010;116 (ASH Annual Meeting Abstract no. 893)

Faber E, Mužík J, Koza V, Demečková E, Voglová J, Demitrovičová L, et al. Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 – a report from the population-based CAMELIA Registry. Eur. J. Haematol. 2011;87:157–168. PubMed

Zackova D, Klamova H, Dusek L, Muzik J, Polakova KM, Moravcova J, et al. Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials? Am. J. Hematol. 2011;86:318–321. PubMed

Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS) Blood. 2010;116:3758–3765. PubMed PMC

de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained response in an intention-to-treat analysis. J. Clin. Oncol. 2008;26:3358–3363. PubMed

Cross NC, Melo JV, Feng L, Goldman JM. An optimized multiple polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in hematologicalal disorder. Leukemia. 1994;8:186–189. PubMed

Gabert J, Beillard E, Bi VH, van der Velden W, Grimwade D, Pallisgaard N, et al. Standardization and duality control studies of real-time quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia- a Europe against cancer program. Leukemia. 2003;17:2318–2357. PubMed

Rohrbacher M, Hasford J. Epidemiology of chronic myeloid leukaemia (CML) Best Pract. Res. Clin. Haematol. 2009;22:295–302. PubMed

Rohrbacher M, Berger U, Hochhaus A, Metzgeroth G, Adam K, Lahaye T, et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia. 2009;23:602–604. PubMed

Kantarjian H, O'Brien S, Jabbour E, Shan J, Ravandi F, Kadia T, et al. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J. Clin. Oncol. 2011;29:3173–3178. PubMed PMC

O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 2003;348:994–1004. PubMed

Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Müller MC, Pletsch N, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J. Clin. Oncol. 2011;29:1634–1642. PubMed

Jabbour E, Kantarjian H, O'Brien S, Shan J, Quintas-Cardama A, Faderl S, et al. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood. 2011;118:4541–4546. PubMed PMC

Quintás-Cardama A, Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood. 2009;113:6315–6321. PubMed PMC

Quintás-Cardama A, Cortes JE, Kantarjian HM. Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase. Cancer. 2011;117:5261–5270. PubMed PMC